Trial Profile

Phase II Trial of Regorafenib in Patients With Unresectable Hepatocellular Carcinoma After Progression on First Line Atezolizumab Plus Bevacizumab (REGONEXT Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms REGONEXT

Most Recent Events

20 Jan 2024 Results assessing the efficacy and safety of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab presented at the 2024 Gastrointestinal Cancers Symposium.
25 Apr 2023 Status changed from recruiting to active, no longer recruiting.
21 Jan 2023 Trial design presented at the 2023 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com